Head-To-Head Contrast: Ophthotech Corporation (OPHT) vs. Stemline Therapeutics (STML)

Ophthotech Corporation (NASDAQ: OPHT) and Stemline Therapeutics (NASDAQ:STML) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability.

Profitability

This table compares Ophthotech Corporation and Stemline Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ophthotech Corporation 26.69% -69.40% 24.91%
Stemline Therapeutics -4,689.63% -75.50% -64.20%

Analyst Ratings

This is a summary of recent ratings for Ophthotech Corporation and Stemline Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ophthotech Corporation 0 12 0 0 2.00
Stemline Therapeutics 0 0 6 0 3.00

Ophthotech Corporation presently has a consensus price target of $10.00, suggesting a potential upside of 198.51%. Stemline Therapeutics has a consensus price target of $33.40, suggesting a potential upside of 138.57%. Given Ophthotech Corporation’s higher possible upside, analysts plainly believe Ophthotech Corporation is more favorable than Stemline Therapeutics.

Valuation and Earnings

This table compares Ophthotech Corporation and Stemline Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Ophthotech Corporation $50.91 million 2.37 -$193.42 million $1.57 2.13
Stemline Therapeutics $1.04 million 340.44 -$38.30 million ($2.57) -5.45

Stemline Therapeutics has higher revenue, but lower earnings than Ophthotech Corporation. Stemline Therapeutics is trading at a lower price-to-earnings ratio than Ophthotech Corporation, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

62.3% of Ophthotech Corporation shares are owned by institutional investors. Comparatively, 49.0% of Stemline Therapeutics shares are owned by institutional investors. 2.0% of Ophthotech Corporation shares are owned by insiders. Comparatively, 16.7% of Stemline Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk & Volatility

Ophthotech Corporation has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Comparatively, Stemline Therapeutics has a beta of -0.07, suggesting that its share price is 107% less volatile than the S&P 500.

Summary

Ophthotech Corporation beats Stemline Therapeutics on 8 of the 13 factors compared between the two stocks.

Ophthotech Corporation Company Profile

Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness. Its product candidates include Fovista and Zimura. Fovista is designed to target platelet derived growth factor (PDGF) in combination with anti-vascular endothelial growth factor (VEGF) drugs to disrupt the formation of abnormal new blood vessels in wet AMD. Zimura targets complement factor C5, a central component of the complement cascade. The Company has initiated a Phase II/III clinical trial investigating Zimura for treatment of geographic atrophy.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

Receive News & Ratings for Ophthotech Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply